{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Calcineurin+inhibitor+therapy&page=3", "query": { "intervention": "Calcineurin inhibitor therapy", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Calcineurin+inhibitor+therapy&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Calcineurin+inhibitor+therapy&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T14:52:31.084Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02474199", "title": "Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Transplant Recipient", "Living Donor (of the Respective Liver Transplant Recipient)" ], "interventions": [ { "name": "darTregs", "type": "BIOLOGICAL" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Immunosuppression (IS) Withdrawal", "type": "DRUG" }, { "name": "Study Mandated Procedures", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2016-06-06", "completion_date": "2019-12-16", "has_results": true, "last_update_posted_date": "2021-02-09", "last_synced_at": "2026-10-10T14:52:31.084Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • Rochester, Minnesota", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02474199" }, { "nct_id": "NCT01517984", "title": "Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant Recipients" ], "interventions": [ { "name": "Tacrolimus (CNI) Withdrawal", "type": "DRUG" }, { "name": "Standard Immunosuppressive Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2010-11", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-10T14:52:31.084Z", "location_count": 9, "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01517984" }, { "nct_id": "NCT00214201", "title": "Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Primary Renal Transplant" ], "interventions": [ { "name": "Calcineurin inhibitor withdrawal", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2003-05", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2012-10-03", "last_synced_at": "2026-10-10T14:52:31.084Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00214201" }, { "nct_id": "NCT03828019", "title": "Adalimumab vs. Conventional Immunosuppression for Uveitis Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Uveitis" ], "interventions": [ { "name": "Adalimumab (ADA)", "type": "BIOLOGICAL" }, { "name": "Conventional immunosuppression (CON)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "JHSPH Center for Clinical Trials", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 227, "start_date": "2019-09-16", "completion_date": "2024-09-09", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-10T14:52:31.084Z", "location_count": 19, "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03828019" }, { "nct_id": "NCT01950819", "title": "Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "End Stage Renal Disease (ESRD)", "Chronic Kidney Disease (CKD)", "Hemodialysis", "Renal Replacement Therapy", "Renal Transplantation" ], "interventions": [ { "name": "Induction therapy", "type": "BIOLOGICAL" }, { "name": "Corticosteroids", "type": "DRUG" }, { "name": "EVR+rCNI", "type": "DRUG" }, { "name": "MPA+sCNI", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2037, "start_date": "2013-12-03", "completion_date": "2018-01-17", "has_results": true, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-10-10T14:52:31.084Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01950819" }, { "nct_id": "NCT04202679", "title": "Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurodermatitis" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moisturizers", "type": "DRUG" }, { "name": "Low to medium potent topical corticosteroids", "type": "DRUG" }, { "name": "Topical calcineurin inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 160, "start_date": "2020-01-16", "completion_date": "2021-11-22", "has_results": true, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-10-10T14:52:31.084Z", "location_count": 7, "location_summary": "Fort Smith, Arkansas • Sacramento, California • Pembroke Pines, Florida + 4 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Plainfield", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04202679" }, { "nct_id": "NCT02711826", "title": "Treg Therapy in Subclinical Inflammation in Kidney Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Transplant", "Adult Living Donor Kidney Transplant Recipients", "Renal Transplant", "Living Kidney Donor" ], "interventions": [ { "name": "Polyclonal Regulatory T Cells", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Mycophenolic acid", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Biopsy, Kidney", "type": "PROCEDURE" }, { "name": "Blood Draw", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "IS regimen conversion", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2016-09-20", "completion_date": "2023-08-04", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-10T14:52:31.084Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711826" }, { "nct_id": "NCT05621759", "title": "Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Vs Host Disease" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 27, "start_date": "2022-09-07", "completion_date": "2027-01-30", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-10T14:52:31.084Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05621759" }, { "nct_id": "NCT00137345", "title": "Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Transplant" ], "interventions": [ { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 500, "start_date": "2005-06", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2013-02-08", "last_synced_at": "2026-10-10T14:52:31.084Z", "location_count": 23, "location_summary": "San Diego, California • San Francisco, California • Denver, Colorado + 18 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00137345" }, { "nct_id": "NCT05917522", "title": "Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant" ], "interventions": [ { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Standard of Care at US Transplant Centers", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 800, "start_date": "2023-12-07", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-10T14:52:31.084Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05917522" } ] }